PSMA antibody (AA 161-190)
Quick Overview for PSMA antibody (AA 161-190) (ABIN3030978)
Target
See all PSMA (FOLH1) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 161-190
-
Purpose
- PSMA Antibody / FOLH1
-
Cross-Reactivity (Details)
- Expected species reactivity: Mouse, Rat, Pig
-
Purification
- Antigen affinity
-
Immunogen
- A portion of amino acids 161-190 from the human protein was used as the immunogen for this PSMA antibody.
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
- Titration of the PSMA antibody may be required due to differences in protocols and secondary/substrate sensitivity.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- In 1X PBS, pH 7.4, with 0.09 % sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Aliquot the PSMA antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- PSMA (FOLH1) (Folate Hydrolase (Prostate-Specific Membrane Antigen) 1 (FOLH1))
-
Alternative Name
- PSMA
-
Background
- GCPII (Glutamate carboxypeptidase 2) also called FOLH1 and PSMA (Prostate-Specific Membrane Antigen) is a zinc metalloenzyme that resides in membranes. Most of the enzyme resides in the extracellular space. GCPII is a class II membrane glycoprotein. It catalyzes the hydrolysis of N-acetylaspartylglutamate (NAAG) to glutamate and N-acetylaspartate (NAA). Neuroscientists primarily use the term NAALADase in their studies, while those studying folate metabolism use folate hydrolase, and those studying prostate cancer or oncology, PSMA. All of which refer to the same protein, glutamate carboxypeptidase II. PSMA is strongly expressed in the human prostate, being a hundredfold greater than the expression in most other tissues. In cancer, it is upregulated in expression and has been called the second-most-upregulated gene in prostate cancer, with increase of 8- to 12-fold over the noncancerous prostate. In human prostate cancer, the higher expressing tumors are associated with quicker time to progression and a greater percentage of patients suffering relapse. [Wiki]
-
UniProt
- Q04609
Target
-